{"component": "contracts", "props": {"contracts": [{"intro": "", "id": "h94G2Wk4uDd", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465913039615/a13-11504_3ex1d1.htm", "category_name": "Underwriting Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "May 9th, 2013", "published": true, "pretty": null, "uri": "/contracts/h94G2Wk4uDd", "title": "Isis Pharmaceuticals, Inc. 9,000,000 shares of common stock, par value $0.001 per share Underwriting Agreement", "group_id": "h94G2Wk4uDd", "group_samples": [{"label": "Underwriting Agreement (Forest City Enterprises Inc)", "uri": "/contracts/27322Yio5fj", "published": true}, {"label": "Underwriting Agreement (Solazyme Inc)", "uri": "/contracts/Heelisg0go", "published": true}, {"label": "Underwriting Agreement (TRW Automotive Holdings Corp)", "uri": "/contracts/h65dfOy934y", "published": true}], "group_size": 6, "tags": [{"name": "Underwriting Agreement", "type": "category", "uri": "/contracts/tagged/underwriting-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "6eptETcBgKx", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000091205702013013/a2075186zex-10_42.txt", "category_name": "Non-Employee Directors' Stock Option Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "April 1st, 2002", "published": true, "pretty": null, "uri": "/contracts/6eptETcBgKx", "title": "2002 NON-EMPLOYEE DIRECTORS' STOCK OPTION PLAN GRANT NOTICE", "group_id": "4hSJ39f1CvQ", "group_samples": [{"label": "Non Employee Director's Stock Option Agreement (Thermadyne Holdings Corp /De)", "uri": "/contracts/4hSJ39f1CvQ", "published": true}, {"label": "Non Employee Directors Stock Option Agreement (Inhibitex, Inc.)", "uri": "/contracts/gC0BRRfTmP", "published": true}, {"label": "Non Employee Directors' Stock Option Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/6eptETcBgKx", "published": true}], "group_size": 5, "tags": [{"name": "Non-Employee Directors' Stock Option Agreement", "type": "category", "uri": "/contracts/tagged/non-employee-directors-stock-option-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "YrY7USwEbV", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000091205702000293/a2067158zex-10_6.txt", "category_name": "Clinical Supply Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "January 4th, 2002", "published": true, "pretty": null, "uri": "/contracts/YrY7USwEbV", "title": "ARTICLE 1 DEFINITIONS", "group_id": "7NniDkcnHl5", "group_samples": [{"label": "Clinical Supply Agreement (Seattle Genetics Inc /Wa)", "uri": "/contracts/7NniDkcnHl5", "published": true}, {"label": "Clinical Supply Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/YrY7USwEbV", "published": true}, {"label": "Clinical Supply Agreement (Drugabuse Sciences Inc)", "uri": "/contracts/1zY8yAekDqg", "published": true}], "group_size": 5, "tags": [{"name": "Clinical Supply Agreement", "type": "category", "uri": "/contracts/tagged/clinical-supply-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "REGISTRATION RIGHTS AGREEMENT, dated as of January 23, 2007, by and among Isis Pharmaceuticals, Inc. (together with any successor entity, herein referred to as the \u201cIssuer\u201d), and Lehman Brothers Inc., as representative (the \u201cRepresentative\u201d) of the initial purchasers attached hereto on Schedule I (collectively, the \u201cInitial Purchasers\u201d).", "id": "iExyBY6cnc6", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465907004281/a07-2517_1ex4d2.htm", "category_name": "Registration Rights Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "January 24th, 2007", "published": true, "pretty": null, "uri": "/contracts/iExyBY6cnc6", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "bDKEmWQASfG", "group_samples": [{"label": "Registration Rights Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/iExyBY6cnc6", "published": true}, {"label": "Registration Rights Agreement (Global Industries LTD)", "uri": "/contracts/bDKEmWQASfG", "published": true}, {"label": "Registration Rights Agreement (Dexcom Inc)", "uri": "/contracts/8pxFRJ8FTtb", "published": true}], "group_size": 4, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (the \u201cAgreement\u201d) is entered into as of the 5th day of January, 2017 (the \u201cExecution Date\u201d) by and between Akcea Therapeutics, Inc., a Delaware corporation, having its principal place of business at 55 Cambridge Parkway, Cambridge, MA 02142 USA, together with each of Akcea\u2019s Affiliates (\u201cAkcea\u201d), andNovartis Pharma AG, a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland (\u201cNovartis\u201d). Novartis and Akcea each may be referred to herein individually as a \u201cParty\u201d or collectively as the \u201cParties.\u201d Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement. As of the Effective Date, Akcea is a wholly-owned subsidiary of Ionis Pharmaceuticals, Inc. (\u201cIonis\u201d) and therefore Akcea and Ionis are Affiliates.", "id": "lwg6mb8rfTi", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401517000033/ex10_1.htm", "category_name": "Strategic Collaboration, Option and License Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "May 9th, 2017", "published": true, "pretty": null, "uri": "/contracts/lwg6mb8rfTi", "title": "Strategic Collaboration, Option and License Agreement Between Akcea Therapeutics, Inc. And Novartis Pharma AG", "group_id": "cIfi7ZSFifj", "group_samples": [{"label": "Strategic Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/lwg6mb8rfTi", "published": true}, {"label": "Strategic Collaboration, Option and License Agreement (Akcea Therapeutics, Inc.)", "uri": "/contracts/cIfi7ZSFifj", "published": true}, {"label": "Strategic Collaboration, Option and License Agreement (Akcea Therapeutics, Inc.)", "uri": "/contracts/ipMa91ZVQmH", "published": true}], "group_size": 4, "tags": [{"name": "Strategic Collaboration, Option and License Agreement", "type": "category", "uri": "/contracts/tagged/strategic-collaboration-option-and-license-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Second Amended and Restated Strategic Advisory Services Agreement is entered into and made effective as of January 9, 2020, and amends and restates the Strategic Advisory Service Agreement dated January 15, 2018, as amended on March 22, 2019, by and between B. Lynne Parshall and Ionis Pharmaceuticals, Inc. (\u201cIonis\u201d).", "id": "cLtngYqyRMR", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000114036120000641/ex10_1.htm", "category_name": "Strategic Advisory Services Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "January 10th, 2020", "published": true, "pretty": null, "uri": "/contracts/cLtngYqyRMR", "title": "SECOND AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT (\u201cSUMMARY PAGE\u201d)", "group_id": "2OkVbnTsiBA", "group_samples": [{"label": "Strategic Advisory Services Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/cLtngYqyRMR", "published": true}, {"label": "Strategic Advisory Services Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/de6vBAxMRZ2", "published": true}, {"label": "Strategic Advisory Services Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/2OkVbnTsiBA", "published": true}], "group_size": 3, "tags": [{"name": "Strategic Advisory Services Agreement", "type": "category", "uri": "/contracts/tagged/strategic-advisory-services-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}, {"intro": "", "id": "l1vpfDtbtOO", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000093639297001079/1.txt", "category_name": "Supplemental Stock Option Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "August 12th, 1997", "published": true, "pretty": null, "uri": "/contracts/l1vpfDtbtOO", "title": "1 EXHIBIT 10.1", "group_id": "2yNQphXwAJE", "group_samples": [{"label": "Supplemental Stock Option Agreement (Globenet Communications Group LTD)", "uri": "/contracts/idsb9xh1uVo", "published": true}, {"label": "Supplemental Stock Option Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/2yNQphXwAJE", "published": true}, {"label": "Supplemental Stock Option Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/l1vpfDtbtOO", "published": true}], "group_size": 3, "tags": [{"name": "Supplemental Stock Option Agreement", "type": "category", "uri": "/contracts/tagged/supplemental-stock-option-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS FOUNDING INVESTOR RIGHTS AGREEMENT (the \u201cAgreement\u201d) is entered into as of the 1st day of January 2009, by and among Regulus Therapeutics Inc., a Delaware corporation (the \u201cCompany\u201d) on the one hand, and Isis Pharmaceuticals, Inc., a Delaware Corporation (\u201cIsis\u201d) and Alnylam Pharmaceuticals, Inc., a Delaware corporation (\u201cAlnylam\u201d) who are each holders of the Company\u2019s Series A Preferred Stock (the \u201cPreferred Stock\u201d) on the other hand. Isis and Alnylam may be referred to hereinafter collectively as the \u201cFounding Investors\u201d and each individually as a \u201cFounding Investor\u201d. The Company, Isis and Alnylam may be referred to hereinafter collectively as the \u201cParties\u201d and each individually as a \u201cParty\u201d.", "id": "bXEGFAaQDC7", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465909030408/a09-11285_1ex10d2.htm", "category_name": "Founding Investor Rights Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "May 7th, 2009", "published": true, "pretty": null, "uri": "/contracts/bXEGFAaQDC7", "title": "REGULUS THERAPEUTICS INC. FOUNDING INVESTOR RIGHTS AGREEMENT", "group_id": "4M0jve2mUU3", "group_samples": [{"label": "Founding Investor Rights Agreement (Regulus Therapeutics Inc.)", "uri": "/contracts/cksib68uEg1", "published": true}, {"label": "Founding Investor Rights Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/bXEGFAaQDC7", "published": true}, {"label": "Founding Investor Rights Agreement (Alnylam Pharmaceuticals, Inc.)", "uri": "/contracts/4M0jve2mUU3", "published": true}], "group_size": 3, "tags": [{"name": "Founding Investor Rights Agreement", "type": "category", "uri": "/contracts/tagged/founding-investor-rights-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "c7udwQFzNuP", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000093639299001378/1.txt", "category_name": "Common Stock Purchase Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "November 22nd, 1999", "published": true, "pretty": null, "uri": "/contracts/c7udwQFzNuP", "title": "1 EXHIBIT 1.1 COMMON STOCK PURCHASE AGREEMENT DATED AS OF _____________, 1999 BY AND BETWEEN ISIS PHARMACEUTICALS, INC.", "group_id": "803X4fSCIpu", "group_samples": [{"label": "Common Stock Purchase Agreement (Axys Pharmecueticals Inc)", "uri": "/contracts/803X4fSCIpu", "published": true}, {"label": "Common Stock Purchase Agreement (Symphonix Devices Inc)", "uri": "/contracts/6g0LKea1EgL", "published": true}, {"label": "Common Stock Purchase Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/c7udwQFzNuP", "published": true}], "group_size": 3, "tags": [{"name": "Common Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/common-stock-purchase-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Stock Purchase Agreement (\u201cAgreement\u201d) is entered into as of January 5, 2017 (the \u201cExecution Date\u201d), by and among Novartis Pharma AG (\u201cNovartis\u201d), a company organized under the laws of Switzerland, having its principal place of business at Lichtstrasse 35, 4002 Basel, Switzerland, Ionis Pharmaceuticals, Inc. (\u201cIonis\u201d), a Delaware corporation having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010, and Akcea Therapeutics, Inc. (\u201cAkcea\u201d), a Delaware corporation having its principal place of business at 55 Cambridge Parkway, Suite 100, Cambridge, MA 02142.", "id": "aqgNzCANLYW", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401517000033/ex10_2.htm", "category_name": "Stock Purchase Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "May 9th, 2017", "published": true, "pretty": null, "uri": "/contracts/aqgNzCANLYW", "title": "STOCK PURCHASE AGREEMENT", "group_id": "aqgNzCANLYW", "group_samples": [{"label": "Stock Purchase Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/aqgNzCANLYW", "published": true}, {"label": "Stock Purchase Agreement (Akcea Therapeutics, Inc.)", "uri": "/contracts/fbLq9A37qXF", "published": true}, {"label": "Stock Purchase Agreement (Akcea Therapeutics, Inc.)", "uri": "/contracts/htXThvZLA9K", "published": true}], "group_size": 3, "tags": [{"name": "Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/stock-purchase-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "", "id": "6ldH7fUYtkR", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000093639200000158/6.txt", "category_name": "Supplemental Stock Option Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "March 28th, 2000", "published": true, "pretty": null, "uri": "/contracts/6ldH7fUYtkR", "title": "ISIS PHARMACEUTICALS, INC. SUPPLEMENTAL STOCK OPTION AGREEMENT (DIRECTOR)", "group_id": "cmLwkNOJ7F8", "group_samples": [{"label": "Supplemental Stock Option Agreement (Valence Technology Inc)", "uri": "/contracts/cmLwkNOJ7F8", "published": true}, {"label": "Supplemental Stock Option Agreement (Valence Technology Inc)", "uri": "/contracts/fx6jBi7mYrR", "published": true}, {"label": "Supplemental Stock Option Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/6ldH7fUYtkR", "published": true}], "group_size": 3, "tags": [{"name": "Supplemental Stock Option Agreement", "type": "category", "uri": "/contracts/tagged/supplemental-stock-option-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "", "id": "1BiD4py4A40", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000091205701530761/a2058321zex-2_3.txt", "category_name": "Registration Rights and Standstill Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "August 29th, 2001", "published": true, "pretty": null, "uri": "/contracts/1BiD4py4A40", "title": "ISIS PHARMACEUTICALS, INC. REGISTRATION RIGHTS AND STANDSTILL AGREEMENT THIS REGISTRATION RIGHTS AND STANDSTILL AGREEMENT (the \"Agreement\") is made as of August 17, 2001 by and between ISIS PHARMACEUTICALS, INC., a Delaware corporation (the...", "group_id": "jQmefaoMBXE", "group_samples": [{"label": "Registration Rights and Standstill Agreement (Exide Corp)", "uri": "/contracts/4HemJqLCkIZ", "published": true}, {"label": "Registration Rights and Standstill Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/1BiD4py4A40", "published": true}, {"label": "Registration Rights and Standstill Agreement (Pacific Dunlop Holdings Usa Inc)", "uri": "/contracts/jQmefaoMBXE", "published": true}], "group_size": 3, "tags": [{"name": "Registration Rights and Standstill Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-and-standstill-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Collaboration and License Agreement (the \u201cAgreement\u201d) is made and entered into effective as of July 9, 2021 (the \u201cEffective Date\u201d) by and between BicycleTx Limited, a company incorporated in England and Wales with a place of business at Building 900, Babraham Research Campus, Cambridge CB22 3AT, UK (\u201cBicycleTx\u201d), and Ionis Pharmaceuticals, Inc., a Delaware corporation with a principal place of business at 2855 Gazelle Court, Carlsbad, California 92010, USA (\u201cIonis\u201d). BicycleTx and Ionis are referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties\u201d.", "id": "1ldg9ozEF5z", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401521000166/ex10-2.htm", "category_name": "Collaboration and License Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "November 3rd, 2021", "published": true, "pretty": null, "uri": "/contracts/1ldg9ozEF5z", "title": "COLLABORATION AND LICENSE AGREEMENT between BICYCLETX LIMITED and IONIS PHARMACEUTICALS, INC. Dated as of July 9, 2021", "group_id": "1ldg9ozEF5z", "group_samples": [{"label": "Collaboration and License Agreement (BICYCLE THERAPEUTICS PLC)", "uri": "/contracts/20b05j5r2fk", "published": true}, {"label": "Collaboration and License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/1ldg9ozEF5z", "published": true}], "group_size": 2, "tags": [{"name": "Collaboration and License Agreement", "type": "category", "uri": "/contracts/tagged/collaboration-and-license-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "hWGLkoUrYBb", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000093639299000362/4.txt", "category_name": "Common Stock Purchase Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "March 31st, 1999", "published": true, "pretty": null, "uri": "/contracts/hWGLkoUrYBb", "title": "EXHIBIT 99.1 COMMON STOCK PURCHASE AGREEMENT DATED AS OF ___________________, 1999 BY AND BETWEEN ISIS PHARMACEUTICALS, INC.", "group_id": "1oxInhvT5UK", "group_samples": [{"label": "Common Stock Purchase Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/hWGLkoUrYBb", "published": true}, {"label": "Common Stock Purchase Agreement (Hickory Furniture Co)", "uri": "/contracts/1oxInhvT5UK", "published": true}], "group_size": 2, "tags": [{"name": "Common Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/common-stock-purchase-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH \u201c[***]\u201d.", "id": "26v4ttYPwGB", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401521000056/exhibit10_56.htm", "category_name": "Research Collaboration, Option and License Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "February 24th, 2021", "published": true, "pretty": null, "uri": "/contracts/26v4ttYPwGB", "title": "Contract", "group_id": "26v4ttYPwGB", "group_samples": [{"label": "Research Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/26v4ttYPwGB", "published": true}, {"label": "Research Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/L7MXyr6I1Z", "published": true}], "group_size": 2, "tags": [{"name": "Research Collaboration, Option and License Agreement", "type": "category", "uri": "/contracts/tagged/research-collaboration-option-and-license-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "THIS CERTIFIES THAT, for value received, SYMPHONY GENISIS HOLDINGS LLC, with its principal office at 7361 Calhoun Place, Suite 325, Rockville, MD 20850, or its assigns (the \u201cHolder\u201d), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Isis Pharmaceuticals, Inc., a Delaware corporation, with its principal office at 1896 Rutherford Road, Carlsbad, CA 92008-7208 (the \u201cCompany\u201d) up to four million two hundred fifty thousand (4,250,000) shares of the Common Stock of the Company (the \u201cCommon Stock\u201d), subject to adjustment as provided herein. This Warrant is being issued pursuant to the terms of the Warrant Purchase Agreement, dated April 7, 2006, by and among the Company and the Holder (the \u201cWarrant Purchase Agreement\u201d). Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in the Warrant Purchase Agreement.", "id": "gsf2dKVnbi2", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465906033066/a06-9337_1ex10d6.htm", "category_name": "Warrant Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "May 10th, 2006", "published": true, "pretty": null, "uri": "/contracts/gsf2dKVnbi2", "title": "ISIS PHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCK", "group_id": "2GGstN8Wqnc", "group_samples": [{"label": "Warrant Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/gsf2dKVnbi2", "published": true}, {"label": "Warrant Agreement (Symphony Capital Partners LP)", "uri": "/contracts/2GGstN8Wqnc", "published": true}], "group_size": 2, "tags": [{"name": "Warrant Agreement", "type": "category", "uri": "/contracts/tagged/warrant-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This STRATEGIC COLLABORATION AGREEMENT (the \u201cAgreement\u201d) is entered into as of the 31st day of July, 2015 (the \u201cExecution Date\u201d) by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (\u201cIsis\u201d), and AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 S\u00f6dert\u00e4lje, Sweden (\u201cAstraZeneca\u201d). AstraZeneca and Isis each may be referred to herein individually as a \u201cParty\u201d or collectively as the \u201cParties.\u201d Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices, exhibits and schedules are a part of this Agreement.", "id": "7AmF4p653oI", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000114036116069460/ex10_1.htm", "category_name": "Strategic Collaboration Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "June 10th, 2016", "published": true, "pretty": null, "uri": "/contracts/7AmF4p653oI", "title": "Strategic Collaboration Agreement Between Isis Pharmaceuticals, Inc., And AstraZeneca AB", "group_id": "3jW9vRfQShD", "group_samples": [{"label": "Strategic Collaboration Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/7AmF4p653oI", "published": true}, {"label": "Strategic Collaboration Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/3jW9vRfQShD", "published": true}], "group_size": 2, "tags": [{"name": "Strategic Collaboration Agreement", "type": "category", "uri": "/contracts/tagged/strategic-collaboration-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This SECOND AMENDED AND RESTATED STRATEGIC NEUROLOGY DRUG DISCOVERY AND DEVELOPMENT COLLABORATION, OPTION AND LICENSE AGREEMENT (the \u201cAgreement\u201d) is entered into as of the 17th day of October, 2018 (the \u201cSecond Amendment Date\u201d) by and between Ionis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (\u201cIonis\u201d), and Biogen MA Inc., a Massachusetts corporation, having its principal place of business at 225 Binney Street, Cambridge, MA 02142 (\u201cBiogen\u201d). Biogen and Ionis each may be referred to herein individually as a \u201cParty\u201d or collectively as the \u201cParties.\u201d Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.", "id": "5QQ8kSgUDvm", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401519000045/exhibit10_68.htm", "category_name": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "March 1st, 2019", "published": true, "pretty": null, "uri": "/contracts/5QQ8kSgUDvm", "title": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals, Inc. And Biogen MA Inc. Dated October 17, 2018", "group_id": "5QQ8kSgUDvm", "group_samples": [{"label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/5QQ8kSgUDvm", "published": true}, {"label": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/7yICmZPouEt", "published": true}], "group_size": 2, "tags": [{"name": "Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement", "type": "category", "uri": "/contracts/tagged/strategic-neurology-drug-discovery-and-development-collaboration-option-and-license-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This Subcontract Agreement, effective [ ] is made between SCIENCE APPLICATIONS INTERNATIONAL CORPORATION (hereinafter known as \u201cBuyer\u201d), a Delaware corporation with principal offices in San Diego, California, and Isis Pharmaceuticals, Inc. (hereinafter known as \u201cSeller\u201d), a corporation, with principal offices in Carlsbad, California. The effort to be performed by Seller under this Subcontract will be part of Buyer\u2019s Prime Contract # [ ] that has been issued by [ ]. The work, defined in Attachment I (Statement of Work and Schedule) will be performed on a Time and Material/Labor Hour basis, in accordance with Schedule A (Specific Terms and Conditions), and any referenced document in 18.0 Order of Precedence clause of this agreement.", "id": "eZaRqvwvI8P", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465905053679/a05-18037_1ex10d5.htm", "category_name": "Subcontract Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "November 9th, 2005", "published": true, "pretty": null, "uri": "/contracts/eZaRqvwvI8P", "title": "SUBCONTRACT AGREEMENT Time and Material / Labor Hour", "group_id": "5cfoDlMRdgi", "group_samples": [{"label": "Subcontract Agreement", "uri": "/contracts/5cfoDlMRdgi", "published": true}, {"label": "Subcontract Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/eZaRqvwvI8P", "published": true}], "group_size": 2, "tags": [{"name": "Subcontract Agreement", "type": "category", "uri": "/contracts/tagged/subcontract-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "", "id": "5dtCxOjxdwZ", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465908074716/a08-29740_1ex10d2.htm", "category_name": "Severance Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "December 5th, 2008", "published": true, "pretty": null, "uri": "/contracts/5dtCxOjxdwZ", "title": "VIA HAND DELIVERY", "group_id": "5dtCxOjxdwZ", "group_samples": [{"label": "Severance Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/eNvaBJEY4NA", "published": true}, {"label": "Severance Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/5dtCxOjxdwZ", "published": true}], "group_size": 2, "tags": [{"name": "Severance Agreement", "type": "category", "uri": "/contracts/tagged/severance-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}, {"intro": "This License and Co-Development Agreement (together with all Exhibits, Schedules and other attachments hereto, this \u201cAgreement\u201d), is dated as of the 24th day of June, 2008 (the \u201cExecution Date\u201d), by and between Genzyme Corporation, a Massachusetts corporation (\u201cGenzyme\u201d) and Isis Pharmaceuticals, Inc., a Delaware corporation (\u201cIsis\u201d). Genzyme and Isis each may be referred to herein individually as a \u201cParty\u201d or collectively as the \u201cParties.\u201d", "id": "5ofSeFITj5B", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465908051496/a08-18933_1ex10d1.htm", "category_name": "License and Co-Development Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "August 11th, 2008", "published": true, "pretty": null, "uri": "/contracts/5ofSeFITj5B", "title": "LICENSE AND CO-DEVELOPMENT AGREEMENT BY AND BETWEEN GENZYME CORPORATION AND ISIS PHARMACEUTICALS, INC. June 24, 2008", "group_id": "5ofSeFITj5B", "group_samples": [{"label": "License and Co Development Agreement (Genzyme Corp)", "uri": "/contracts/8UoKt1FI2k1", "published": true}, {"label": "License and Co Development Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/5ofSeFITj5B", "published": true}], "group_size": 2, "tags": [{"name": "License and Co-Development Agreement", "type": "category", "uri": "/contracts/tagged/license-and-co-development-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "6mjSIVQ31xy", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465908069665/a08-25609_1ex10d1.htm", "category_name": "License Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "November 10th, 2008", "published": true, "pretty": null, "uri": "/contracts/6mjSIVQ31xy", "title": "AMENDED AND RESTATED LICENSE AGREEMENT", "group_id": "6OAWcoNU0Qn", "group_samples": [{"label": "License Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/6mjSIVQ31xy", "published": true}, {"label": "License Agreement (Oncogenex Pharmaceuticals, Inc.)", "uri": "/contracts/6OAWcoNU0Qn", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "British Columbia", "type": "jurisdiction", "uri": "/contracts/tagged/british-columbia-ca"}]}, {"intro": "ENVIRONMENTAL INDEMNITY AGREEMENT (this \u201cAgreement\u201d) made as of the 18th day of July, 2017 by IONIS GAZELLE, LLC a Delaware limited liability company, having an office at 2855 Gazelle Court, Carlsbad, California 92010 (\u201cBorrower\u201d), and IONIS PHARMACEUTICALS, INC., a Delaware corporation, having an office at 2855 Gazelle Court, Carlsbad, California 92010 (\u201cGuarantor\u201d, and together with Borrower, \u201cIndemnitor\u201d), in favor of UBS AG, by and through its branch office at 1285 Avenue of the Americas, New York, New York, having an address at 1285 Avenue of the Americas, 11th Floor, New York, New York 10019 (\u201cIndemnitee\u201d) and other Indemnified Parties (defined below).", "id": "7ivOubrrxkO", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_5.htm", "category_name": "Environmental Indemnity Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "July 21st, 2017", "published": true, "pretty": null, "uri": "/contracts/7ivOubrrxkO", "title": "ENVIRONMENTAL INDEMNITY AGREEMENT", "group_id": "7ivOubrrxkO", "group_samples": [{"label": "Environmental Indemnity Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/7ivOubrrxkO", "published": true}, {"label": "Environmental Indemnity Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/bgtCqeBYzfY", "published": true}], "group_size": 2, "tags": [{"name": "Environmental Indemnity Agreement", "type": "category", "uri": "/contracts/tagged/environmental-indemnity-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This GUARANTY (this \u201cGuaranty\u201d) is executed as of July 18, 2017 by IONIS PHARMACEUTICALS, INC., a Delaware corporation, having an address at 2855 Gazelle Court, Carlsbad, California 92010 (whether one or more collectively referred to as \u201cGuarantor\u201d), for the benefit of UBS AG, by and through its branch office at 1285 Avenue of the Americas, New York, New York, having an address at 1285 Avenue of the Americas, 11th Floor, New York, New York 10019 (together with its successors and assigns, \u201cLender\u201d).", "id": "7uFK0wF8OC0", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_3.htm", "category_name": "Guaranty", "company_name": "Ionis Pharmaceuticals Inc", "created": "July 21st, 2017", "published": true, "pretty": null, "uri": "/contracts/7uFK0wF8OC0", "title": "GUARANTY", "group_id": "7uFK0wF8OC0", "group_samples": [{"label": "Guaranty (Ionis Pharmaceuticals Inc)", "uri": "/contracts/7uFK0wF8OC0", "published": true}, {"label": "Guaranty (Ionis Pharmaceuticals Inc)", "uri": "/contracts/8SECo9APjhv", "published": true}], "group_size": 2, "tags": [{"name": "Guaranty", "type": "category", "uri": "/contracts/tagged/guaranty"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "8l1CLe4GvE0", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401524000187/ex10-2.htm", "category_name": "License Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "August 1st, 2024", "published": true, "pretty": null, "uri": "/contracts/8l1CLe4GvE0", "title": "Amended and Restated License Agreement By and Between Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd.", "group_id": "8l1CLe4GvE0", "group_samples": [{"label": "License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/gPgTLJXk7S9", "published": true}, {"label": "License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/8l1CLe4GvE0", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS DEVELOPMENT, COMMERCIALIZATION, COLLABORATION, AND LICENSE AGREEMENT is made and entered into as of March 14, 2018 (the \u201cExecution Date\u201d), by and between Akcea Therapeutics, Inc., a Delaware corporation (\u201cAkcea\u201d), and Ionis Pharmaceuticals, Inc., a Delaware corporation (\u201cIonis\u201d). Akcea and Ionis each may be referred to herein individually as a \u201cParty,\u201d or collectively as the \u201cParties.\u201d", "id": "lb5hGUyOgjH", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401518000060/ex10_2.htm", "category_name": "License Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "May 7th, 2018", "published": true, "pretty": null, "uri": "/contracts/lb5hGUyOgjH", "title": "LICENSE AGREEMENT", "group_id": "OJp8iwZMz4", "group_samples": [{"label": "License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/lb5hGUyOgjH", "published": true}, {"label": "License Agreement (Akcea Therapeutics, Inc.)", "uri": "/contracts/OJp8iwZMz4", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "Pursuant to your Stock Option Grant Notice (\u201cGrant Notice\u201d) and this Option Agreement, Ionis Pharmaceuticals, Inc. (the \u201cCompany\u201d) has granted you an option under its 2011 Equity Incentive Plan (the \u201cPlan\u201d) to purchase the number of shares of the Company\u2019s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Capitalized terms not explicitly defined in this Option Agreement but defined in the Plan shall have the same definitions as in the Plan.", "id": "fHis0D7NoSI", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401523000105/exhibit10-13.htm", "category_name": "Option Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "February 22nd, 2023", "published": true, "pretty": null, "uri": "/contracts/fHis0D7NoSI", "title": "Ionis Pharmaceuticals, Inc. Option Agreement (Nonstatutory Stock Option)", "group_id": "aZtprFO2GDp", "group_samples": [{"label": "Option Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/fHis0D7NoSI", "published": true}, {"label": "Option Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/aZtprFO2GDp", "published": true}], "group_size": 2, "tags": [{"name": "Option Agreement", "type": "category", "uri": "/contracts/tagged/option-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amended and Restated License and Collaboration Agreement (the \u201cAgreement\u201d) is entered into as of the 1st day of January, 2009 (the \u201cAmendment Effective Date\u201d) by and among ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business at 300 Third Street, Cambridge, Massachusetts 02142 (\u201cAlnylam\u201d), ISIS PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business at 1896 Rutherford Road, Carlsbad, California 92008 (\u201cIsis\u201d, and each of Alnylam and Isis, a \u201cLicensor\u201d and together, the \u201cLicensors\u201d), and REGULUS THERAPEUTICS INC. (formerly Regulus Therapeutics LLC), a Delaware corporation, with its principal place of business at 1896 Rutherford Road, Carlsbad, California 92008 (\u201cRegulus\u201d).", "id": "dOePRN5k2bB", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465909030408/a09-11285_1ex10d1.htm", "category_name": "License and Collaboration Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "May 7th, 2009", "published": true, "pretty": null, "uri": "/contracts/dOePRN5k2bB", "title": "AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT", "group_id": "b23xXhiV83V", "group_samples": [{"label": "License and Collaboration Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/dOePRN5k2bB", "published": true}, {"label": "License and Collaboration Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/b23xXhiV83V", "published": true}], "group_size": 2, "tags": [{"name": "License and Collaboration Agreement", "type": "category", "uri": "/contracts/tagged/license-and-collaboration-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (the \u201cAgreement\u201d) is entered into as of the 22nd day of December, 2014 (the \u201cEffective Date\u201d), by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010 (\u201cIsis\u201d), and Janssen Biotech Inc., a Pennsylvania company, with principal offices located at 800/850 Ridgeview Road, Horsham, PA 19044 (\u201cJBI\u201d) JBI and Isis each may be referred to herein individually as a \u201cParty\u201d or collectively as the \u201cParties.\u201d Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.", "id": "ifHZPNK2QAv", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401521000056/exhibit10_46.htm", "category_name": "Research Collaboration, Option and License Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "February 24th, 2021", "published": true, "pretty": null, "uri": "/contracts/ifHZPNK2QAv", "title": "Research Collaboration, Option and License Agreement Between Isis Pharmaceuticals, Inc. And Janssen Biotech Inc.", "group_id": "b7pJIUqi7OD", "group_samples": [{"label": "Research Collaboration, Option and License Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/ifHZPNK2QAv", "published": true}, {"label": "Research Collaboration, Option and License Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/b7pJIUqi7OD", "published": true}], "group_size": 2, "tags": [{"name": "Research Collaboration, Option and License Agreement", "type": "category", "uri": "/contracts/tagged/research-collaboration-option-and-license-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "", "id": "22FQbn1Khuz", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000091205701527777/a2056057zex-10_3.txt", "category_name": "Collaborative Research and License Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "August 10th, 2001", "published": true, "pretty": null, "uri": "/contracts/22FQbn1Khuz", "title": "RECITALS", "group_id": "cXb7fIx5fUK", "group_samples": [{"label": "Collaborative Research and License Agreement (3 Dimensional Pharmaceuticals Inc)", "uri": "/contracts/cXb7fIx5fUK", "published": true}, {"label": "Collaborative Research and License Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/22FQbn1Khuz", "published": true}], "group_size": 2, "tags": [{"name": "Collaborative Research and License Agreement", "type": "category", "uri": "/contracts/tagged/collaborative-research-and-license-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "THIS NON-EXCLUSIVE TECHNOLOGY ALLIANCE AND OPTION AGREEMENT (the \u201cAgreement\u201d) is made and entered into this June 17, 2010 (the \u201cEffective Date\u201d), by and between SANOFI-AVENTIS, a French Corporation (\u201cSanofi\u201d) having a place of business at 174 avenue de France, 75013, Paris, France and registered in the Paris Trade and Company Register under no. 395 030 844, and REGULUS THERAPEUTICS INC., a Delaware Corporation (\u201cRegulus\u201d) having a place of business at 1896 Rutherford Road, Carlsbad, California 92008. Sanofi and Regulus each may be referred to herein individually as a \u201cParty,\u201d or collectively as the \u201cParties.\u201d", "id": "hXO582cmjXd", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000110465910043177/a10-12790_1ex10d2.htm", "category_name": "Non-Exclusive Technology Alliance and Option Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "August 9th, 2010", "published": true, "pretty": null, "uri": "/contracts/hXO582cmjXd", "title": "NON-EXCLUSIVE TECHNOLOGY ALLIANCE AND OPTION AGREEMENT between REGULUS THERAPEUTICS INC. and SANOFI-AVENTIS", "group_id": "chg6zq20H2w", "group_samples": [{"label": "Non Exclusive Technology Alliance and Option Agreement (Regulus Therapeutics Inc.)", "uri": "/contracts/chg6zq20H2w", "published": true}, {"label": "Non Exclusive Technology Alliance and Option Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/hXO582cmjXd", "published": true}], "group_size": 2, "tags": [{"name": "Non-Exclusive Technology Alliance and Option Agreement", "type": "category", "uri": "/contracts/tagged/non-exclusive-technology-alliance-and-option-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This LICENSE AGREEMENT (the \u201cAgreement\u201d) is entered into as of the 1st day of May, 2015 (the \u201cExecution Date\u201d) by and between Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, CA 92010, USA (\u201cIsis\u201d), and Bayer Pharma AG, a company organized under the laws of Germany, having its principal place of business at Muellerstra\u00dfe 178, 13353 Berlin, Germany (\u201cBayer\u201d). Bayer and Isis each may be referred to herein individually as a \u201cParty\u201d or collectively as the \u201cParties.\u201d Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in Appendix 1. All attached appendices and schedules are a part of this Agreement.", "id": "hLei9pJAW9e", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401515000077/ex10_1.htm", "category_name": "License Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "August 5th, 2015", "published": true, "pretty": null, "uri": "/contracts/hLei9pJAW9e", "title": "License Agreement", "group_id": "hLei9pJAW9e", "group_samples": [{"label": "License Agreement", "uri": "/contracts/iaIGwuTXx4b", "published": true}, {"label": "License Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/hLei9pJAW9e", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS COLLABORATION AND CO-DEVELOPMENT AGREEMENT (\"Agreement\") is made and entered into effective as of November 16, 2001 (the \"Effective Date\"), by and among ONCOGENEX TECHNOLOGIES INC., having offices at Suite 400, 609 - 14th Street N.W., Calgary, Alberta T2N 2A1 (\"OncoGenex\") and ISIS PHARMACEUTICALS, INC., having principal offices at 2292 Faraday Avenue, Carlsbad CA 92008 (\"Isis\"). OncoGenex and Isis each may be referred to herein individually as a \"Party,\" or collectively as the \"Parties.\"", "id": "iI67wReCMKk", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000091205701542819/a2065583zex-10_1.htm", "category_name": "Collaboration and Co-Development Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "December 12th, 2001", "published": true, "pretty": null, "uri": "/contracts/iI67wReCMKk", "title": "COLLABORATION AND CO-DEVELOPMENT AGREEMENT", "group_id": "iI67wReCMKk", "group_samples": [{"label": "Collaboration and Co Development Agreement (Oncogenex Technologies Inc)", "uri": "/contracts/kYnOyh52Jb2", "published": true}, {"label": "Collaboration and Co Development Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/iI67wReCMKk", "published": true}], "group_size": 2, "tags": [{"name": "Collaboration and Co-Development Agreement", "type": "category", "uri": "/contracts/tagged/collaboration-and-co-development-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "British Columbia", "type": "jurisdiction", "uri": "/contracts/tagged/british-columbia-ca"}]}, {"intro": "", "id": "69aHI9wYLsy", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000093639298000472/3.txt", "category_name": "Asset Purchase Agreement", "company_name": "Isis Pharmaceuticals Inc", "created": "March 19th, 1998", "published": true, "pretty": null, "uri": "/contracts/69aHI9wYLsy", "title": "RECITALS", "group_id": "kGLfIU0MV2w", "group_samples": [{"label": "Asset Purchase Agreement (Isis Pharmaceuticals Inc)", "uri": "/contracts/69aHI9wYLsy", "published": true}, {"label": "Asset Purchase Agreement (Usa Talks Com Inc)", "uri": "/contracts/kGLfIU0MV2w", "published": true}], "group_size": 2, "tags": [{"name": "Asset Purchase Agreement", "type": "category", "uri": "/contracts/tagged/asset-purchase-agreement"}, {"name": "Isis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/isis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}, {"intro": "This PURCHASE AND SALE AGREEMENT (as the same may be amended, modified, or supplemented from time to time in accordance with the terms hereof, this \u201cAgreement\u201d), dated effective for all purposes as of October 20, 2022, is by and between IONIS GAZELLE, LLC, a Delaware limited liability company (\u201cSeller\u201d), and 2850 2855 & 2859 GAZELLE OWNER (DE) LLC, a Delaware limited liability company (together with its successors and/or assigns, collectively, \u201cBuyer\u201d).", "id": "10CNuyyO1dj", "source_url": "https://www.sec.gov/Archives/edgar/data/874015/000087401523000105/exhibit10-24.htm", "category_name": "Purchase and Sale Agreement", "company_name": "Ionis Pharmaceuticals Inc", "created": "February 22nd, 2023", "published": true, "pretty": null, "uri": "/contracts/10CNuyyO1dj", "title": "PURCHASE AND SALE AGREEMENT", "group_id": "10CNuyyO1dj", "group_samples": [{"label": "Purchase and Sale Agreement (Ionis Pharmaceuticals Inc)", "uri": "/contracts/10CNuyyO1dj", "published": true}], "group_size": 1, "tags": [{"name": "Purchase and Sale Agreement", "type": "category", "uri": "/contracts/tagged/purchase-and-sale-agreement"}, {"name": "Ionis Pharmaceuticals Inc", "type": "company", "uri": "/company/874015/ionis-pharmaceuticals-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "California", "type": "jurisdiction", "uri": "/contracts/tagged/california-us"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLMTBDTnV5eU8xZGoYACAB", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAYKGQoIZ3JvdXBfaWQSDRoLZktxUHhwWTZGNGcYACAB"}}